Europe's Heatwave Sparks Investment Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: CNBC
- Climate Change Impact: Multiple European countries are experiencing record heatwaves with temperatures exceeding 40 degrees Celsius, disrupting power supplies and closing schools, which directly affects the economy and increases the demand for climate adaptation and energy efficiency investments.
- Insurance Sector Opportunities: Ninety One's Global Sustainable Equity Fund is focusing on insurance companies like Aon and Intact Financial, believing that climate change will drive structural growth in the insurance industry, particularly for firms offering climate risk management solutions.
- Energy Transition Trends: As temperatures rise, companies like Johnson Controls and Siemens are seeing a surge in demand for HVAC products, with modern heat pumps serving as effective cooling devices to meet heightened summer demands.
- Grid Modernization Needs: The surge in electricity demand is putting pressure on aging power infrastructure, with companies like ABB, Schneider Electric, and Siemens poised to benefit from investments in grid modernization, providing essential equipment to enhance power supply capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 243.140
Low
223.00
Averages
252.00
High
289.00
Current: 243.140
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie to Announce Q2 2026 Financial Results on July 31
- Earnings Announcement: AbbVie will release its Q2 2026 financial results on July 31 before market open, providing crucial financial metrics and business performance updates that will assist investors in assessing the company's financial health.
- Live Webcast: The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible through AbbVie's Investor Relations website, ensuring transparency and enhancing engagement with investors.
- Performance Review and Outlook: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, reflecting the company's efforts and achievements in addressing significant health issues, which may impact future market performance.
- Company Mission and Vision: AbbVie is committed to discovering and delivering innovative medicines that address current and future medical challenges, emphasizing its products and services within the Allergan Aesthetics portfolio, showcasing the company's long-term strategic positioning in the healthcare industry.
See More
Europe's Heatwave Sparks Investment Opportunities
- Climate Change Impact: Multiple European countries are experiencing record heatwaves with temperatures exceeding 40 degrees Celsius, disrupting power supplies and closing schools, which directly affects the economy and increases the demand for climate adaptation and energy efficiency investments.
- Insurance Sector Opportunities: Ninety One's Global Sustainable Equity Fund is focusing on insurance companies like Aon and Intact Financial, believing that climate change will drive structural growth in the insurance industry, particularly for firms offering climate risk management solutions.
- Energy Transition Trends: As temperatures rise, companies like Johnson Controls and Siemens are seeing a surge in demand for HVAC products, with modern heat pumps serving as effective cooling devices to meet heightened summer demands.
- Grid Modernization Needs: The surge in electricity demand is putting pressure on aging power infrastructure, with companies like ABB, Schneider Electric, and Siemens poised to benefit from investments in grid modernization, providing essential equipment to enhance power supply capabilities.
See More
FDA Approves AbbVie's Skyrizi for Children with Psoriasis
- Pediatric Approval: The US FDA has approved AbbVie's Skyrizi (risankizumab) for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, marking a significant advancement in the company's pediatric dermatology portfolio.
- Clinical Trial Validation: This approval is based on results from the phase 3 OptIMMize psoriasis clinical trial program, demonstrating Skyrizi's efficacy in alleviating patient symptoms, which provides AbbVie with a strong clinical foundation in a competitive biopharmaceutical market.
- Dosage Innovation: The FDA also approved a 55 mg pre-filled syringe specifically for patients weighing less than 40 kg, which will enable more pediatric patients to receive appropriate treatment, thereby expanding Skyrizi's applicability.
- Optimistic Market Outlook: With the introduction of Skyrizi in the pediatric population, AbbVie is poised to capture a larger share of the psoriasis treatment market, enhancing its competitive position in the biopharmaceutical sector and laying the groundwork for future revenue growth.
See More
FDA Approves SKYRIZI for Pediatric Psoriasis and Arthritis
- FDA Approval for New Indication: AbbVie announced that SKYRIZI (risankizumab-rzaa) has received FDA approval for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis in children aged six and older, marking the first use of this drug in pediatric populations and is expected to significantly enhance the quality of life for affected children.
- Innovative Dosage Form: The newly approved 55 mg pre-filled syringe is specifically designed for children weighing less than 40 kg, providing a more precise weight-based dosing option that ensures treatment efficacy and safety, thereby expanding the applicability of SKYRIZI.
- Clinical Trial Support: The pediatric indication for SKYRIZI is backed by data from the Phase 3 OptIMMize clinical trial program, demonstrating efficacy and safety in treating pediatric patients, which enhances physician confidence in the drug and may promote its broader clinical use.
- Patient Support Programs: AbbVie is committed to helping patients access SKYRIZI through patient support programs and co-pay cards that can reduce out-of-pocket costs to as low as $0 per month, ensuring that more children can receive treatment, reflecting the company's dedication to improving patient lives.
See More
SKYRIZI Approved for Pediatric Psoriasis Treatment
- New Treatment Option for Children: SKYRIZI (risankizumab-rzaa) has received FDA approval for children aged six and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis, marking a significant advancement in pediatric immunotherapy.
- Dosing Innovation: The newly approved 55 mg pre-filled syringe is specifically designed for patients weighing less than 40 kg, ensuring more precise dosing management, which enhances treatment efficacy and safety for younger patients.
- Clinical Data Support: The approval is backed by data from the Phase 3 OptIMMize clinical trial, demonstrating significant improvements in sPGA and PASI scores at Week 16, indicating long-term efficacy in pediatric patients.
- Patient Support Programs: AbbVie is committed to helping patients access SKYRIZI through patient support programs and co-pay cards that may reduce out-of-pocket costs, ensuring that more children can receive treatment and enhancing the company's social responsibility in pediatric health.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
AbbVie to Announce Q2 2026 Financial Results on July 31
- Earnings Announcement: AbbVie will release its Q2 2026 financial results on July 31 before market open, providing crucial financial metrics and business performance updates that will assist investors in assessing the company's financial health.
- Live Webcast: The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible through AbbVie's Investor Relations website, ensuring transparency and enhancing engagement with investors.
- Performance Review and Outlook: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, reflecting the company's efforts and achievements in addressing significant health issues, which may impact future market performance.
- Company Mission and Vision: AbbVie is committed to discovering and delivering innovative medicines that address current and future medical challenges, emphasizing its products and services within the Allergan Aesthetics portfolio, showcasing the company's long-term strategic positioning in the healthcare industry.
See More
Europe's Heatwave Sparks Investment Opportunities
- Climate Change Impact: Multiple European countries are experiencing record heatwaves with temperatures exceeding 40 degrees Celsius, disrupting power supplies and closing schools, which directly affects the economy and increases the demand for climate adaptation and energy efficiency investments.
- Insurance Sector Opportunities: Ninety One's Global Sustainable Equity Fund is focusing on insurance companies like Aon and Intact Financial, believing that climate change will drive structural growth in the insurance industry, particularly for firms offering climate risk management solutions.
- Energy Transition Trends: As temperatures rise, companies like Johnson Controls and Siemens are seeing a surge in demand for HVAC products, with modern heat pumps serving as effective cooling devices to meet heightened summer demands.
- Grid Modernization Needs: The surge in electricity demand is putting pressure on aging power infrastructure, with companies like ABB, Schneider Electric, and Siemens poised to benefit from investments in grid modernization, providing essential equipment to enhance power supply capabilities.
See More
FDA Approves AbbVie's Skyrizi for Children with Psoriasis
- Pediatric Approval: The US FDA has approved AbbVie's Skyrizi (risankizumab) for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, marking a significant advancement in the company's pediatric dermatology portfolio.
- Clinical Trial Validation: This approval is based on results from the phase 3 OptIMMize psoriasis clinical trial program, demonstrating Skyrizi's efficacy in alleviating patient symptoms, which provides AbbVie with a strong clinical foundation in a competitive biopharmaceutical market.
- Dosage Innovation: The FDA also approved a 55 mg pre-filled syringe specifically for patients weighing less than 40 kg, which will enable more pediatric patients to receive appropriate treatment, thereby expanding Skyrizi's applicability.
- Optimistic Market Outlook: With the introduction of Skyrizi in the pediatric population, AbbVie is poised to capture a larger share of the psoriasis treatment market, enhancing its competitive position in the biopharmaceutical sector and laying the groundwork for future revenue growth.
See More
FDA Approves SKYRIZI for Pediatric Psoriasis and Arthritis
- FDA Approval for New Indication: AbbVie announced that SKYRIZI (risankizumab-rzaa) has received FDA approval for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis in children aged six and older, marking the first use of this drug in pediatric populations and is expected to significantly enhance the quality of life for affected children.
- Innovative Dosage Form: The newly approved 55 mg pre-filled syringe is specifically designed for children weighing less than 40 kg, providing a more precise weight-based dosing option that ensures treatment efficacy and safety, thereby expanding the applicability of SKYRIZI.
- Clinical Trial Support: The pediatric indication for SKYRIZI is backed by data from the Phase 3 OptIMMize clinical trial program, demonstrating efficacy and safety in treating pediatric patients, which enhances physician confidence in the drug and may promote its broader clinical use.
- Patient Support Programs: AbbVie is committed to helping patients access SKYRIZI through patient support programs and co-pay cards that can reduce out-of-pocket costs to as low as $0 per month, ensuring that more children can receive treatment, reflecting the company's dedication to improving patient lives.
See More
SKYRIZI Approved for Pediatric Psoriasis Treatment
- New Treatment Option for Children: SKYRIZI (risankizumab-rzaa) has received FDA approval for children aged six and older with moderate-to-severe plaque psoriasis and active psoriatic arthritis, marking a significant advancement in pediatric immunotherapy.
- Dosing Innovation: The newly approved 55 mg pre-filled syringe is specifically designed for patients weighing less than 40 kg, ensuring more precise dosing management, which enhances treatment efficacy and safety for younger patients.
- Clinical Data Support: The approval is backed by data from the Phase 3 OptIMMize clinical trial, demonstrating significant improvements in sPGA and PASI scores at Week 16, indicating long-term efficacy in pediatric patients.
- Patient Support Programs: AbbVie is committed to helping patients access SKYRIZI through patient support programs and co-pay cards that may reduce out-of-pocket costs, ensuring that more children can receive treatment and enhancing the company's social responsibility in pediatric health.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
